Check out your Company Bowl for anonymous work chats.
๐๏ธ Make sure to read this article from Campus Sanofi, a Spanish-speaking educational platform for healthcare professionals, where they feature Quibim to explain from the inside how it is now possible for clinicians to diagnose earlier, monitor in real time and personalize treatments with the power of AI. โ๐๐ ๐ฐ๐ท๐ฆ๐ณ๐ค๐ฐ๐ฎ๐ฆ๐ด ๐ต๐ฉ๐ฆ ๐ญ๐ช๐ฎ๐ช๐ต๐ข๐ต๐ช๐ฐ๐ฏ๐ด ๐ฐ๐ง ๐ต๐ณ๐ข๐ฅ๐ช๐ต๐ช๐ฐ๐ฏ๐ข๐ญ ๐ณ๐ข๐ฅ๐ช๐ฐ๐ฎ๐ช๐ค๐ด, ๐ฐ๐ง๐ง๐ฆ๐ณ๐ช๐ฏ๐จ ๐ฎ๐ฐ๐ณ๐ฆ ๐ข๐ค๐ค๐ถ๐ณ๐ข๐ต๐ฆ ๐ฑ๐ณ๐ฐ๐จ๐ฏ๐ฐ๐ด๐ฆ๐ด ๐ข๐ฏ๐ฅ ๐ช๐ฎ๐ฑ๐ณ๐ฐ๐ท๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ๐ณ๐ข๐ฑ๐ฆ๐ถ๐ต๐ช๐ค ๐ฆ๐ง๐ง๐ช๐ค๐ข๐ค๐บ ๐ช๐ฏ ๐ฐ๐ฏ๐ค๐ฐ๐ญ๐ฐ๐จ๐บ".
The current standard for assessing tumor response in clinical trials - RECIST, performed by human readers - can be challenged by investigator bias, subjectivity in lesion selection and measurement variability. To address this, Quibim has partnered with Friends of Cancer Research on its artificial intelligence-based measurement of response evaluation criteria in solid tumors (ai.RECIST) project. The ai.RECIST project evaluates AI-based tumor measurement tools to: โ๏ธ Provide consistent and accurate tumor measurements โ๏ธ Align with expert RECIST readouts โ๏ธ Reduce variability and streamline trials Check Quibim's AI-supported RECIST tool, embedded in QP-Insights: https://bit.ly/3ELhH3p #aiRECIST #AIinResearch
The PROVIDENCE study, sponsored by Johnson & Johnson, S.A. in collaboration with Quibim, leverages artificial intelligence to predict metastatic relapse in patients with intermediate- to high-risk localized #ProstateCancer. ๐ Clinical data and diagnostic imaging are analyzed using the QP-Insightsยฎ platform to support non-invasive, real-time risk stratification. Interim results (n=127) demonstrate promising predictive performance for biochemical recurrence (AUC: 0.79), with surgery, PSA levels, and ISUP grade identified as key clinical predictors. Final results, currently in progress, will incorporate quantitative imaging biomarkers to further advance personalized treatment strategies. Read the full study here: https://bit.ly/42qjK4X #AIinHealthcare #MedicalImaging #Oncology #PrecisionMedicine
Our CEO and Co-Founder Dr. รngel Alberich-Bayarri will join the stage at the European Conference on Interventional Oncology (ECIO) in Rotterdam to discuss: ๐๐ต๐ฉ๐ช๐ค๐ข๐ญ, ๐๐ณ๐ข๐ค๐ต๐ช๐ค๐ข๐ญ ๐ข๐ฏ๐ฅ ๐๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ท๐ฆ ๐๐ด๐ฆ๐ด ๐ฐ๐ง ๐๐ ๐ช๐ฏ ๐๐ฏ๐ต๐ฆ๐ณ๐ท๐ฆ๐ฏ๐ต๐ช๐ฐ๐ฏ๐ข๐ญ ๐๐ฏ๐ค๐ฐ๐ญ๐ฐ๐จ๐บ. ๐๏ธ April 13, 2025 ๐ฅ 10:30โ12:00 CET ๐ Auditorium 2, Rotterdam Ahoy Convention Centre - Rotterdam, The Netherlands ๐ค Moderators: Fernando Gรณmez Muรฑoz & Bernhard Meyer Join us for a critical conversation on how AI can be implemented responsibly to improve patient care. #InterventionalOncology #AIinHealthcare #EthicalAI #ECIO2025
This morning, we participated in the first edition of ๐๐ช๐ค๐ณ๐ฐ๐ด๐ฐ๐ง๐ต ๐๐ฆ๐ข๐ญ๐ต๐ฉ๐ค๐ข๐ณ๐ฆ ๐๐ข๐บ in Madrid, an initiative organized by SEDISA (The Spanish Society of Healthcare Managers) in collaboration with Microsoft. The event aims to modernize the Spanish healthcare system through AI-powered technological solutions. Representing Quibim, our Chief Operations Officer Alberto Valiente Montoro, and Director of Business Development - EMEA, LATAM & APAC Javier Pizcueta Pastor, participated in the panel on the medical diagnosis and early detection of high-impact diseases. They shared how we apply artificial intelligence to transform the way these conditions are identified and managed. ๐ A big thank you for creating this space for innovation and fostering stronger collaboration between healthcare and technology. #DigitalHealth #ArtificialIntelligence #HealthcareInnovation
๐ข Our CEO & Co-Founder รngel Alberich-Bayarri participated in a Campus Sanofi Unboxing episode to share his vision on how AI is already helping radiologists detect diseases more accurately. Spanish-speaking healthcare professionals are sure to be interested! ๐
Q1 2025 was a significant quarter at Quibim: ๐ก Discover the latest tech and research in AI for healthcare ๐ข Key publications and clinical perspectives ๐ Performance highlights and company news Stay ahead of the curve, subscribe to our newsletter! ๐ฉ https://bit.ly/4lnusC5 #MedicalImaging #HealthAI #Innovation
With renewed leadership, FDA clearance for QP-Prostate CAD and a $50M Series A, Quibim enters a new era of growth and strategic expansion that will certainly scale and shape the future of precision healthcare. Introducing our new Board of Directors: โช๏ธ Tom Tynes, Founder of T2 MedTech, LLC (Independent Director) โช๏ธ Pierre Socha, Partner at Amadeus Capital Partners โช๏ธ Romain Lavault, General Partner at Partech โช๏ธ Guillem Masferrer, Partner at Asabys Partners โช๏ธ Jose Mesa, Partner at COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and Buenavista Equity Partners (formerly GED Capital)โs representative on the Board โช๏ธ Dr. รngel Alberich-Bayarri, CEO & Co-Founder of Quibim One of the new members of the Board of Directors is Tom Tynes, who joins as an independent director. Tom brings a wealth of experience, having led the launch, profitable growth, and success of several medical device companies over the past 30 years. https://bit.ly/4i6Qczc
๐ AI is transforming how we develop new treatments, accelerating the path from discovery to #patientcare. By leveraging machine learning, data mining, and predictive modeling, AI is optimizing every stage of drug developmentโmaking the process faster, smarter, and more precise. #MachineLearning #MedicalInnovation #AIinHealth
CADt, CADe, CADx โ Whatโs the Difference? AI-based computer-aided triage (CADt), detection (CADe) and diagnosis (CADx) are becoming increasingly important in medical imaging: โก ๐๐๐๐ญ โ Identifies potentially urgent cases to prioritize their review, without making a diagnosis. ๐ฉบ ๐๐๐๐ โ Flags suspicious regions on medical images to assist as a second reader. ๐ฌ ๐๐๐๐ฑ โ Analyzes and characterizes lesions to support diagnostic decisions. So... is CADe/x a game-changer in radiology? We break it all down in our latest blog ๐ https://bit.ly/4hZIuaa #AIinHealthcare #Radiology #MedicalImaging #AIPoweredCAD #PrecisionMedicine
